Skip to content
Friday 31 July 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
City PM

European business, markets and politics

FTSE 100
10,868.72
-0.26%
DAX
25,634.61
+0.09%
CAC 40
8,523.42
+0.45%
STOXX 50
6,361.07
+0.26%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE
Sponsored Ad Feature is produced by an advertiser with the specific intent to promote a product and is not produced by the City PM team.
Friday 21 August 2020 9:36 am

Awareness is essential for saving lives

By:

Add as a preferred source on Google

Heart valve disease currently affects over 1.5 million people in the UK, with that number set to exceed 3 million by 2056. Despite its prevalence, awareness of the signs and symptoms is still limited.  

Heart Valve Voice is a dedicated heart valve disease charity formed by a collection of people with real experiences of heart valve disease, who aim to raise awareness of this important issue. Its ranks include a multi-disciplinary group of experts in the field (cardiologists, cardiac surgeons, GPs), cardiac patient societies and patients. 

The key symptoms of heart valve disease are breathlessness, dizziness, chest pain and fatigue. Early detection of valve disease is key to good patient outcomes, so anyone with symptoms should contact their GP for a simple stethoscope check. When a patient develops severe heart valve disease it becomes life threatening, and they are at risk of heart failure, heart attack and stroke. 

“Symptom recognition is critical to positive patient outcomes, so awareness is crucial,” says Consultant Cardiologist, Dr Dan Blackman. “We must also address inequalities in access to innovative treatments, such as TAVI, where we lag behind our European and transatlantic counterparts, if we are to achieve a best practice that delivers for every patient.” 

heartvalvevoice.com

Read more

Almirall Announces EMA Acceptance for Filing of Paediatric Registration of Ebglyss (Lebrikizumab) in Atopic Dermatitis in Children 6 Months and Older

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Categories

  • Life&Style

Trending Articles

  • Gino D’Acampo restaurants face HMRC winding-up order

  • PwC thought leadership reports ‘100 per cent AI generated’

  • BP quits North Sea after tax grab

  • Lloyd’s of London allows staff to work from home as heatwave hits the capital

  • Foxtons hits out at Renters’ Rights Act as profit halves

More from City PM

  • Almirall Announces EMA Acceptance for Filing of Paediatric Registration of Ebglyss (Lebrikizumab) in Atopic Dermatitis in Children 6 Months and Older

    Business Wire
  • Dompé Doses First Patient in Phase 3 Study of Cenegermin-bkbj in NAION

    Business Wire
  • Top investment bank: Starmer and Reeves left UK ‘no better off than they found it’

    Economics
    Keir Starmer and Rachel Reeves discuss the Great British Summer Savings scheme at a press conference podium with banners b...
  • Prothena to Report Second Quarter 2026 Financial Results on August 6

    Business Wire
  • Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis

    Business Wire
  • Verdiva Bio Appoints Cardiometabolic Leader Steve Marso as Chief Medical Officer

    Business Wire
  • Verdiva Bio Initiates Phase 1 Study of VRB-103, a Selective Oral Amylin Peptide Analog With Weekly Dosing Potential

    Business Wire
  • VoxNeuro Receives FDA 510(k) Clearance for Cognitive Function Neuroimaging (cfNI) Software – An Objective EEG/ERP Brain Health Assessment

    Business Wire
CityPM

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About City PM
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 City PM Ltd · Published by CityPM Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook